JPH0329046B2 - - Google Patents

Info

Publication number
JPH0329046B2
JPH0329046B2 JP58197886A JP19788683A JPH0329046B2 JP H0329046 B2 JPH0329046 B2 JP H0329046B2 JP 58197886 A JP58197886 A JP 58197886A JP 19788683 A JP19788683 A JP 19788683A JP H0329046 B2 JPH0329046 B2 JP H0329046B2
Authority
JP
Japan
Prior art keywords
pipesanate
hydrochloride
aluminum silicate
drying
starch hydrolyzate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP58197886A
Other languages
Japanese (ja)
Other versions
JPS6089479A (en
Inventor
Mitsuji Inagaki
Minoru Okuda
Fumio Okumura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fuji Chemical Industries Co Ltd
Original Assignee
Fuji Chemical Industries Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuji Chemical Industries Co Ltd filed Critical Fuji Chemical Industries Co Ltd
Priority to JP58197886A priority Critical patent/JPS6089479A/en
Publication of JPS6089479A publication Critical patent/JPS6089479A/en
Publication of JPH0329046B2 publication Critical patent/JPH0329046B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明は安定な塩酸ピペサネート製剤の製造方
法に関するものである。更に詳しくは、塩酸ピペ
サネートの水溶液にケイ酸アルミニウム及びでん
粉加水分解物を加えて、造粒乾燥することを特長
とする安定な塩酸ピペサネート製剤の製造方法に
関するものである。 本発明の目的物の主成分である塩酸ピペサネー
トは第3級アミンの塩酸塩であつて、有用なコリ
ン遮断剤として主に制酸剤と配合されて常用され
る水溶性医薬品である。構造的にはベンジル酸と
ピペリジンエタノールとのエステルであるところ
から、この結晶は水分、熱、塩基性物質によつて
分解をうけやすいことが知られており、従つて塩
基性の薬物である制酸剤と配合された製剤の場合
特に分解されやすく、その製剤の有効期間が短い
ことが大きな欠点である。 従来から不安定な水溶性医薬品の安定化法とし
て公知な合成又は天然の高分子膜や蝋状物質によ
る被覆法は、操作が繁雑であつたり、被覆膜が不
均一なため安定な製品を完全に得ることを得ず、
又、ケイ酸又はケイ酸塩ヒドロゲルによる包蔵化
法は、ヒドロゲルという特殊なものを調製して用
いることや乾燥効率が悪いなどの欠点がある。
又、シクロデキストリンによつて包接化合物とな
す方法にあつては製造コストが高く、工業的に生
産が不適当であつたりして安定生産をみていない
のが現状である。 本発明者らは上記の欠点を改善し、本発明の水
溶性医薬品である塩酸ピペサネート製剤を安定化
し、そして更に好ましくは安価に大量生産を可能
ならしめる目的で鋭意研究を重ねた結果ケイ酸ア
ルミニウム及びでん粉加水分解物のいづれも、
夫々単独で用いて塩酸ピペサネートを安定化する
ことはできないが、両者が共存すれば塩酸ピペサ
ネートが極めて安定になるという驚くべき事実を
発現し、本発明を完成させるに至つた。 本発明を実施するに当たつては、塩酸ピペサネ
ートの水溶液に最初にケイ酸アルミニウムとでん
粉加水分解物を加えるが、両者の注加法は同時、
順次いづれでもよく、本発明の効果に影響を及ぼ
さない。得られた混合液を混和均一撹拌したの
ち、次いで得られたスラリー状混和物を造粒乾燥
するに際しては押出成形ののちマルメライザーで
造粒して棚式乾燥する方法、流動床造粒乾燥、噴
霧造粒乾燥等いづれの造粒乾燥法によつても良い
が、大量に安定生産が可能である点で、造粒と乾
燥を同時に行うことのできる噴霧乾燥が好まし
い。 本発明に使用されているケイ酸アルミニウムは
日本薬局方天然又は合成ケイ酸アルミニウムであ
つて、表面酸性点が多く、しかも吸着能を高める
ための大きな微細構造を有するので好適である。
又でん粉加水分解物は、でん粉を原料に酵素によ
つて加水分解して得られるグルコース残基を基本
骨格にもつ、DexstroseEquivalent値〔でん粉の
品位の表示であつて直接還元糖(ぶどう糖とし
て)/全固形物×100で表す。以下DE値と略称す
る。〕が2〜36の値を有するものであり、好まし
くは吸湿性の低い性質ももつ2〜20のDE値をも
つものであつて、DE値をほとんど有せずグルコ
ース残基の環状構造をもつのが特長のシクロデキ
ストリンはこれに該当しない。 本発明に用いる塩酸ピペサネートの水溶液の濃
度は1〜5w/v%であり、後に行う造粒乾燥の
方法に関係して濃度を選ぶ。即ち造粒後乾燥する
ときは1〜3%、同時に造粒乾燥を行う工程を選
ぶときは2〜5%にする。 又、本発明に用いるケイ酸アルミニウム、でん
粉加水分解物の塩酸ピペサネートに対する配合比
は、ケイ酸アルミニウム粉末の細孔径、細孔容
積、比表面積等の表面物性によつて決まるが、塩
酸ピペサネート1部に対し、ケイ酸アルミニウム
粉末5〜50部、でん粉加水分解物1〜5部を用い
ると良い。又、湿式造粒乾燥の乾燥温度は乾燥法
により異なるが、製剤にかかる品温が50〜60゜が
好ましい。 本発明で得られた安定な塩酸ピペサネート製剤
はそのまま単味の製剤として用いることもできる
が、制酸剤との配合剤とした場合でも長期にわた
り安定性を保つことができる。 本発明の実施例1〜4、参考例1〜2で得られ
た製剤を試験製剤として用い、次の安定性試験を
行い、結果を表,に示した。 安定性試験 〔試験〕試験製剤1.0gをポリセロ包材40×
60mmに密封し、40゜、75%RH及び50゜の条件下で
6ヶ月加速試験し、製剤中の塩酸ピペサネートの
残存量から水分、熱の同製剤に及ぼす影響を調べ
た。 結果を表に示した。
The present invention relates to a method for producing a stable pipesanate hydrochloride formulation. More specifically, the present invention relates to a method for producing a stable pipesanate hydrochloride preparation, which is characterized by adding aluminum silicate and starch hydrolyzate to an aqueous solution of pipesanate hydrochloride, and granulating and drying the mixture. Pipesanate hydrochloride, which is the main component of the object of the present invention, is a hydrochloride of a tertiary amine, and is a water-soluble pharmaceutical commonly used as a useful cholinergic blocker, mainly in combination with antacids. Because it is structurally an ester of benzylic acid and piperidine ethanol, it is known that this crystal is easily decomposed by moisture, heat, and basic substances, and therefore it is difficult to treat the drug as a basic drug. A major drawback is that preparations formulated with acid agents are particularly susceptible to decomposition and have a short shelf life. Coating methods with synthetic or natural polymer membranes or waxy substances, which have traditionally been known as methods for stabilizing unstable water-soluble pharmaceuticals, are complicated to operate and the coating is uneven, making it difficult to obtain stable products. not fully obtained,
In addition, the encapsulation method using silicic acid or silicate hydrogel has drawbacks such as the need to prepare and use a special hydrogel and poor drying efficiency.
Furthermore, in the case of the method of forming an clathrate compound using cyclodextrin, the production cost is high, and production is not suitable for industrial use, so that stable production is not currently possible. The present inventors have conducted extensive research to improve the above-mentioned drawbacks, stabilize the water-soluble pharmaceutical preparation of pipesanate hydrochloride of the present invention, and more preferably enable mass production at low cost.As a result, aluminum silicate and starch hydrolyzate,
They discovered the surprising fact that pipesanate hydrochloride cannot be stabilized by using each alone, but pipesanate hydrochloride becomes extremely stable when both coexist, leading to the completion of the present invention. In carrying out the present invention, aluminum silicate and starch hydrolyzate are first added to an aqueous solution of pipesanate hydrochloride, but both can be added at the same time.
Any order may be used without affecting the effects of the present invention. After mixing and uniformly stirring the obtained liquid mixture, the obtained slurry mixture is then granulated and dried by extrusion molding, granulation with a marmerizer, and shelf drying, fluidized bed granulation drying, Although any granulation and drying method such as spray granulation drying may be used, spray drying is preferred because it allows stable production in large quantities and allows simultaneous granulation and drying. The aluminum silicate used in the present invention is natural or synthetic aluminum silicate according to the Japanese Pharmacopoeia, and is suitable because it has many acidic points on the surface and has a large fine structure for increasing the adsorption capacity.
In addition, starch hydrolyzate has a basic skeleton of glucose residues obtained by hydrolyzing starch with enzymes. Expressed as solids x 100. Hereinafter, it will be abbreviated as DE value. ] has a value of 2 to 36, preferably has a DE value of 2 to 20 with low hygroscopic properties, has almost no DE value and has a cyclic structure of glucose residues This does not apply to cyclodextrin, which is characterized by The concentration of the aqueous solution of pipesanate hydrochloride used in the present invention is 1 to 5 w/v%, and the concentration is selected depending on the method of granulation and drying to be performed later. That is, when drying after granulation, the amount is 1 to 3%, and when selecting a process in which granulation and drying are performed at the same time, the amount is 2 to 5%. Furthermore, the blending ratio of aluminum silicate and starch hydrolyzate used in the present invention to pipesanate hydrochloride is determined by the surface properties of the aluminum silicate powder, such as pore diameter, pore volume, and specific surface area; In contrast, it is preferable to use 5 to 50 parts of aluminum silicate powder and 1 to 5 parts of starch hydrolyzate. Further, the drying temperature for wet granulation drying varies depending on the drying method, but it is preferable that the product temperature of the preparation is 50 to 60°. The stable pipesanate hydrochloride preparation obtained in the present invention can be used as it is as a single preparation, but it can also maintain stability for a long period of time even when combined with an antacid. The following stability tests were conducted using the formulations obtained in Examples 1 to 4 and Reference Examples 1 to 2 of the present invention as test formulations, and the results are shown in the table. Stability test [Test] 1.0g of test preparation was placed in polycello packaging material 40x
The product was sealed to 60 mm and accelerated testing was conducted for 6 months under the conditions of 40°, 75% RH, and 50°, and the effects of moisture and heat on the product were investigated based on the amount of pipesanate hydrochloride remaining in the product. The results are shown in the table.

【表】 〔試験〕試験製剤0.1gと塩基性物質である
日本薬局方沈降炭酸カルシウム又は日本薬局方炭
酸マグネシウムの0.9gを混合した後ポリセロ包
材40×60mmに密封し、以下〔試験と同様に行つ
て塩基性物質の存在下での水分、熱の製剤に及ぼ
す影響を調べた。 その結果を表に示した。
[Table] [Test] After mixing 0.1 g of the test preparation and 0.9 g of the basic substance Japanese Pharmacopoeia precipitated calcium carbonate or Japanese Pharmacopoeia magnesium carbonate, the mixture was sealed in a polycello packaging material 40 x 60 mm. We investigated the effects of moisture and heat on formulations in the presence of basic substances. The results are shown in the table.

【表】 本発明における安定化の機構についての考察は
以下の如くであるが、本発明はこの考案に拘束さ
れるものではない。 試験製剤を用いた安定性試験結果から、参考例
1の単にケイ酸アルミニウム粉末と塩酸ピペサネ
ート水溶液を混和し、当該スラリーを乾燥させた
試験製剤は、安定性試験の6ヶ月後には水分、熱
の影響から製造直後の1/2〜1/3量しか塩酸
ピペサネートは存在せず、又、塩基性物質が存在
すれば更に結果は悪くなる。この結果は、塩酸ピ
ペサネートが乾燥工程中にケイ酸アルミニウムの
粉体表面に晶出するため、完全な吸着包蔵がなさ
れていないことを示している。又一方、参考例2
の単にでん粉加水分解物と塩酸ピペサネート水溶
液とを混和し、当該スラリーを乾燥させた試験製
剤も、上記安定性試験結果と同様塩酸ピペサネー
トは製造直後の1/2〜1/3量しか残存してい
ない。この結果は、でん粉加水分解物が包接力、
吸着力をもつていないため、でん粉加水分解物が
塩酸ピペサネートを被覆保護しないことを示して
いると思われる。 一方、実施例1〜4で得られた試験製剤の加速
虐待条件下での安定性試験を行つても、製剤中の
塩酸ピペサネートの残存量は製造直後と6ヶ月後
とほとんど変わらず、従つて水、熱や塩基物質の
影響を全く受けない。このことは水溶性の塩酸ピ
ペサネート、微細構造を有するケイ酸アルミニウ
ム粉末と水易溶性のでん粉加水分解物の三者であ
るところで、10〜100Å細孔を有するケイ酸アル
ミニウムに塩酸ピペサネート(分子径7Å×20
Å)が表面吸着されそのものを乾燥工程の間にで
ん粉加水分解物が保護コロイド状の被覆膜で覆
い、水分、熱や塩基性物質による影響から塩酸ピ
ペサネートを保護安定化するものと考えられる。 以下実施例を示す。 実施例 1 塩酸ピペサネート50gに60゜の温湯1.67を加
えて3W/V%溶液となし、その溶液に日本薬局
方合成ケイ酸アルミニウム650gを加えて均一に
混和し、次いでDE値2のでん粉加水分解物125g
を加え練合し、42メツシユ篩を用いて造粒後、
50゜で棚式乾燥して細粒を得た。得量785g。 実施例2 塩酸ピペサネート500gに60゜の温湯16.7を加
え3w/v%溶液となし、その溶液に日本薬局方
合成ケイ酸アルミニウム5.5Kg及びDE値20のでん
粉加水分解物2.25Kgを同時に加えて均一に混和
し、当該スラリーを、入熱温度210゜で噴霧乾燥し
て細粒を得た。得量7.76Kg。 実施例 3 実施例2で用いたと同一の塩酸ピペサネート
3w/v%水溶液16.7に、日本薬局方天然ケイ
酸アルミニウム6.5KgとDE値8のでん粉加水分解
物1.25Kgを同時に加えて均一に混和し、当該スラ
リーを入熱温度220゜で噴霧乾燥して細粒を得た。
得量7.82g。 実施例 4 実施例1で用いたと同一の塩酸ピペサネート
3w/v%水溶液1.67に、DE値19のでん粉加水
分解物250gを加えて均一に混和し次いで、日本
薬局方天然ケイ酸アルミニウム525gを加えて練
合し、20メツシユ篩を用いて造粒乾燥後、50゜で
棚式乾燥して細粒を得た。得量768g。 参考例 1 実施例2で用いたと同一の塩酸ピペサネート
3w/v%水溶液16.7に、日本薬局方合成ケイ
酸アルミニウム7.75Kgを加えて均一に混和し、当
該スラリーを入熱温度210゜で噴霧乾燥して細粒を
得た。得量7.8Kg。 参考例 2 実施例1で用いたと同一の塩酸ピペサネート
3w/v水溶液16.7に、に、DE値19のでん粉加
水分解物250gを加えて練合し、42メツシユ篩を
用いて造粒後50゜で棚式乾燥して細粒を得た。得
量282g。
[Table] The stabilization mechanism in the present invention is discussed below, but the present invention is not limited to this idea. From the stability test results using the test formulation, it was found that the test formulation of Reference Example 1, which was prepared by simply mixing aluminum silicate powder and pipesanate hydrochloride aqueous solution and drying the slurry, was free from moisture and heat 6 months after the stability test. Due to its influence, only 1/2 to 1/3 of the amount of pipesanate hydrochloride is present immediately after production, and if a basic substance is present, the results will be even worse. This result shows that pipesanate hydrochloride crystallizes on the surface of the aluminum silicate powder during the drying process, so complete adsorption and encapsulation is not achieved. On the other hand, reference example 2
Similar to the above stability test results, in the test formulation in which the starch hydrolyzate and an aqueous solution of pipesanate hydrochloride were simply mixed and the slurry was dried, only 1/2 to 1/3 of the amount of pipesanate hydrochloride remained immediately after production. do not have. This result shows that starch hydrolyzate has inclusion power,
This seems to indicate that the starch hydrolyzate does not cover and protect pipesanate hydrochloride because it does not have adsorption power. On the other hand, even when the test formulations obtained in Examples 1 to 4 were subjected to stability tests under accelerated abuse conditions, the residual amount of pipesanate hydrochloride in the formulations was almost the same immediately after production and after 6 months, and therefore It is completely unaffected by water, heat and basic substances. This means that water-soluble pipesanate hydrochloride, aluminum silicate powder with a microstructure, and water-soluble starch hydrolyzate are the three components. ×20
It is thought that the starch hydrolyzate is adsorbed on the surface and covered with a protective colloid-like coating film during the drying process, which protects and stabilizes pipesanate hydrochloride from the effects of moisture, heat, and basic substances. Examples are shown below. Example 1 Add 1.67 g of 60° warm water to 50 g of pipesanate hydrochloride to make a 3W/V% solution, add 650 g of Japanese Pharmacopoeia synthetic aluminum silicate to the solution, mix uniformly, and then hydrolyze starch with a DE value of 2. 125g
After adding and kneading and granulating using a 42 mesh sieve,
Fine grains were obtained by shelf drying at 50°. Yield: 785g. Example 2 500 g of pipesanate hydrochloride was added with 16.7 g of warm water at 60° to make a 3 w/v% solution, and 5.5 kg of Japanese Pharmacopoeia synthetic aluminum silicate and 2.25 kg of starch hydrolyzate with a DE value of 20 were simultaneously added to the solution to make it homogeneous. The slurry was spray-dried at a heat input temperature of 210° to obtain fine particles. Yield: 7.76Kg. Example 3 The same pipesanate hydrochloride used in Example 2
6.5 kg of Japanese Pharmacopoeia natural aluminum silicate and 1.25 kg of starch hydrolyzate with a DE value of 8 were simultaneously added to a 3 w/v% aqueous solution of 16.7 kg, mixed uniformly, and the slurry was spray-dried at a heat input temperature of 220°. Fine grains were obtained.
Yield: 7.82g. Example 4 The same pipesanate hydrochloride used in Example 1
Add 250g of starch hydrolyzate with a DE value of 19 to a 3w/v% aqueous solution of 1.67, mix uniformly, then add 525g of Japanese Pharmacopoeia natural aluminum silicate, knead, and granulate and dry using a 20-mesh sieve. After that, it was dried on a shelf at 50° to obtain fine grains. Yield: 768g. Reference example 1 Same pipesanate hydrochloride as used in Example 2
7.75 kg of Japanese Pharmacopoeia synthetic aluminum silicate was added to 16.7% of a 3w/v% aqueous solution and mixed uniformly, and the slurry was spray-dried at a heat input temperature of 210° to obtain fine particles. Yield: 7.8Kg. Reference Example 2 The same pipesanate hydrochloride used in Example 1
250 g of a starch hydrolyzate having a DE value of 19 was added to a 3 w/v aqueous solution of 16.7 and kneaded. After granulation using a 42 mesh sieve, the mixture was dried on a shelf at 50° to obtain fine granules. Yield: 282g.

Claims (1)

【特許請求の範囲】 1 塩酸ピペサネートの水溶液に、ケイ酸アルミ
ニウム及びでん粉加水分解物を加え造粒乾燥する
ことを特長とする安定な塩酸ピペサネート製剤の
製造方法。 2 塩酸ピペサネート1部に対し、ケイ酸アルミ
ニウム5〜50部、でん粉加水分解物1〜5部を使
用する特許請求の範囲第1項記載の安定な塩酸ピ
ペサネートの製造方法。 3 でん粉加水分解物のDE値(但し、DE値はで
ん粉糖の品位の表示であつて、直接還元糖(ぶど
う糖として)/全固形分×100で表される)が2
〜36である特許請求の範囲第1項記載の安定な塩
酸ピペサネート製剤の製造方法。
[Scope of Claims] 1. A method for producing a stable pipesanate hydrochloride preparation, which comprises adding aluminum silicate and starch hydrolyzate to an aqueous solution of pipesanate hydrochloride, and granulating and drying the mixture. 2. The method for producing stable pipesanate hydrochloride according to claim 1, wherein 5 to 50 parts of aluminum silicate and 1 to 5 parts of starch hydrolyzate are used for 1 part of pipesanate hydrochloride. 3 The DE value of the starch hydrolyzate (however, the DE value is an indication of the quality of starch sugar and is expressed as direct reducing sugar (as glucose)/total solids x 100) is 2.
36. A method for producing a stable pipesanate hydrochloride formulation according to claim 1.
JP58197886A 1983-10-21 1983-10-21 Production of stable pipethanate hydrochloride pharmaceutical Granted JPS6089479A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP58197886A JPS6089479A (en) 1983-10-21 1983-10-21 Production of stable pipethanate hydrochloride pharmaceutical

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58197886A JPS6089479A (en) 1983-10-21 1983-10-21 Production of stable pipethanate hydrochloride pharmaceutical

Publications (2)

Publication Number Publication Date
JPS6089479A JPS6089479A (en) 1985-05-20
JPH0329046B2 true JPH0329046B2 (en) 1991-04-23

Family

ID=16381929

Family Applications (1)

Application Number Title Priority Date Filing Date
JP58197886A Granted JPS6089479A (en) 1983-10-21 1983-10-21 Production of stable pipethanate hydrochloride pharmaceutical

Country Status (1)

Country Link
JP (1) JPS6089479A (en)

Also Published As

Publication number Publication date
JPS6089479A (en) 1985-05-20

Similar Documents

Publication Publication Date Title
US5387420A (en) Morphine-containing efferverscent composition
AU594265B2 (en) Therapeutic compositions
JP4621326B2 (en) Teprenone stabilized composition
JP3188657B2 (en) Tablet or granular product
CA1135190A (en) Effervescent analgesic powder
JPS5840529B2 (en) Keikouyou Seizaino Seiho
US3981732A (en) Granular p-phenylenediamine color developing agent
WO2003061646A1 (en) Process for producing granules containing branched amino acids
JP2002527525A (en) High purity composition containing (7α, 17α) -17-hydroxy-7-methyl-19-nor-17-pregnu-5 (10) -en-20-yn-3-one
JPH0329046B2 (en)
JPH03123729A (en) Calcium pantothenate composition and its production
US2930701A (en) Powdered alginate jelly composition and method of preparing the same
JP2002370969A (en) Phospholipidic composition and method for using the same
JPH0724061A (en) Prepation for hemodialysis
US5718923A (en) Melt granulated sucralfate preparations and a process for their production
RU2034533C1 (en) Analgesic antipyretic medicinal agent and a method of its preparing
WO2013182625A1 (en) Pharmaceutical formulation with propargylamine compound
JPH11189547A (en) Stabilized nicorandil medicines and production of the same
US3264117A (en) Free-flowing, non-caking brown sugar
AU663000B2 (en) Adsorbate of an auxiliary mixture and a non-solid active compound for the preparation of pharmaceutical compositions
JPH09100229A (en) Solid preparation containing loxoprofen sodium
JPS58401B2 (en) The antlers of the world
KR960003605B1 (en) Process for preparing oral omeprazole
JPS61236731A (en) Easily flowable powdery composition
JP2010248108A (en) Method for producing sodium ascorbate granule for direct compression